Search Within

Marion Eveillard

Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Center for Hematologic Malignancies (5)
  2. Department of Medicine (5)
  3. Hematologic Malignancies Research (5)
  4. Hematologic Malignancies, Division of (5)
  5. Myeloma (5)
  6. Sloan Kettering Institute Postdocs (5)

More Groups

People
  1. Katie Thoren (6)
  2. Alexander Lesokhin (5)
  3. Carl Landgren (5)
  4. Eric Smith (5)
  5. Hani Hassoun (5)
  6. Malin Hultcrantz (5)

More People

Years
  1. 2021 (1)
  2. 2020 (2)
  3. 2019 (4)
Publications
  1. Blood (2)
  2. British Journal of Haematology (1)
  3. Clinica Chimica Acta (1)
  4. Clinical Biochemistry (1)
  5. Cytometry Part B—Clinical Cytometry (1)
  6. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (2)
  2. American Society of Clinical Oncology (1)
  3. Elsevier Inc. (1)
  4. Elsevier Science BV (1)
  5. John Wiley & Sons (1)
  6. Wiley Blackwell (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Journal Article

    Eveillard, M.; Korde, N.; Ciardiello, A.; Diamond, B.; Lesokhin, A.; Mailankody, S.; Smith, E.; Hassoun, H.; Hultcrantz, M.; Shah, U.; more...
    Clinica Chimica Acta (2021)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
    Journal Article

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry
    Journal Article

    Thoren, K. L.; Eveillard, M.; Chan, P.; Doddi, S.; Cho, S.; Murata, K.
    Clinical Biochemistry (2020)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Early (day 15 post diagnosis) peripheral blood assessment of measurable residual disease in flow cytometry is a strong predictor of outcome in childhood B-lineage lymphoblastic leukemia
    Journal Article

    Loosveld, M.; Nivaggioni, V.; Arnoux, I.; Bernot, D.; Michel, G.; Béné, M. C.; Eveillard, M.
    Cytometry Part B—Clinical Cytometry (2019)

    Fulltext@MSK | Save